ArticleCureus2025
Comparative Analysis of Labile and Stable Coagulation Factors in Fresh Frozen Plasma and Plasma Frozen 24 Hours After Phlebotomy: A Prospective Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Plasma contains coagulation factors, for which it is widely used for patients with coagulation deficiencies. The coagulation factors Factor V and Factor VIII are considered labile factors. The preparation methods and storage periods affect plasma quality. Fresh frozen plasma (FFP) is plasma prepared and frozen within six to eight hours after collection, and frozen plasma (FP24) is prepared and frozen from donor blood units after keeping them at 2-6°C for 16-24 hours after blood collection. The aim of this study is to measure both labile and stable coagulation factor levels and compare them between FFP and frozen plasma (FP24). Materials and methods A total of 100 plasma units were included. The FFPs were prepared as per our institutional standard operating procedure (SOP), and frozen plasma (F24) was prepared according to the Association for the Advancement of Blood and Biotherapies (AABB) guidelines. The coagulation parameters, such as prothrombin time (PT), international normalized ratio (INR), activated partial thromboplastin time (aPTT), and coagulation factors (V, VII, VIII, and fibrinogen), were estimated using a semi-automated coagulometer (Erba ECL-412) in our institution. Result The coagulation parameters, such as PT, INR, and aPTT, were increased, and the coagulation factors were decreased in FP24 plasma as compared to FFP on the day of preparation and after three and six months of storage. Statistically, some coagulation factors showed significant results, whereas others were insignificant. Conclusion The frozen plasma (FP24) can be used therapeutically in stable coagulation factor deficiencies, mostly fibrinogen deficiency, with proper guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.